Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nanjing's Triastek Completes $50 Million Round for 3D Printing of Drugs

publication date: Jun 24, 2021

Triastek of Nanjing completed a $50 million Series B financing to advance its 3D printed pharmaceutical technology. The company has the first drug candidate from its portfolio in clinical trials and is developing the new manufacturing technology for general use. Triastek says Melt Extrusion Deposition (MED®) 3D printing is an additive manufacturing process that precisely deposits each layer of melted excipients, APIs and their mixture materials. It produces a drug delivery system with well-designed geometric structures. The round was co-led by Matrix Partners China and CPE. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital